The role of the PI3K pathway in colorectal cancer

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 1, 2015, Pages 18-30

  Papadatos Pastos, Dionysios ^a   Rabbie, Roy ^a   Ross, Paul ^a   Sarker, Debashis ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; Colorectal; PI3K; PIK3CA; Predictive

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ACETYLSALICYLIC ACID; ALPELISIB; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; BEVACIZUMAB; BUPARLISIB; CETUXIMAB; DACTOLISIB; ENCORAFENIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LINSITINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PILARALISIB; PIMASERTIB; PROTEIN KINASE B INHIBITOR; SELUMETINIB; SONOLISIB; TEMSIROLIMUS; TIVOZANIB; UNINDEXED DRUG; VOXTALISIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG DOSE ESCALATION; DRUG RESISTANCE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERGLYCEMIA; MALIGNANT TRANSFORMATION; METASTASIS; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RASH; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84926116641     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.12.006     Document Type: Review

References (94)

1. Siegel R., Naishadham D., Jemal A. Cancer Statistics. CA Cancer J Clin 2013, 63:11-30.
2. Siegel R., Ward E., Brawley O., et al. Cancer statistics 2011 the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
3. de Gramont A., Bosset J.F., Milan C., et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997, 15:808-815.
4. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
5. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(November):1182-1186.
7. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
8. Porebska I., Harlozińska A., Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2 ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000, 21:105-115.
9. Van Cutsem E., Köhne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
10. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
11. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312.
12. Van Cutsem E., Tabernero J., Lakomy R., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012, 30:3499-3506.
13. Whitman M., Kaplan D.R., Schaffhausen B., et al. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985, 315:239-242.
14. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
15. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
16. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
17. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010, 11:329-341.
18. Katso R., Okkenhaug K., Ahmadi K., et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001, 17:615-675.
19. Samuels Y., Velculescu V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004, 3:1221-1224.
20. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
21. Alessi D.R., James S.R., Downes C.P., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997, 7:261-269.
22. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008, 415:333-344.
23. Wee S., Wiederschain D., Maira S.M., et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 2008, 105:13057-13062.
24. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
25. Rosenberg D.W., Yang S., Pleau D.C., et al. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res 2007, 67:3551-3554.
26. Toyota M., Ho C., Ahuja N., Jair K.W., et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999, 59:2307-2312.
27. Velho S., Moutinho C., Cirnes L., et al. BRAF KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer 2008, 8:255.
28. Kang S., Denley A., Vanhaesebroeck B., et al. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2006, 103:1289-1294.
29. Roy H.K., Olusola B.F., Clemens D.L., et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002, 23:201-205.
30. Waniczek D., Śnietura M., Młynarczyk-Liszka J., et al. PTEN expression profiles in colorectal adenocarcinoma and its precancerous lesions. Pol J Pathol 2013, 64:15-20.
31. Colakoglu T., Yildirim S., Kayaselcuk F., et al. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?. Am J Surg 2008, 195:719-725.
32. Eng C. Genetics of Cowden syndrome: through the looking glass of oncology. Int J Oncol 1998, 12:701-710.
33. Fujishita T., Aoki K., Lane H.A., et al. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A 2008, 105:13544-13549.
34. Maringe C., Walters S., Rachet B., et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007. Acta Oncol 2013, 52:919-932.
35. Labianca R., Nordlinger B., Beretta G.D., et al. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v70-v77.
36. Tournigand C., André T., Bonnetain F., et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012, 30:3353-3360.
37. Kato S., Iida S., Higuchi T., et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 2007, 121:1771-1778.
38. Ogino S., Nosho K., Kirkner G.J., et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009, 27:1477-1484.
39. Ogino S., Liao X., Imamura Y., et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 2013, (November). [Epub ahead of print].
40. Kaur J., Sanyal S.N. PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumour Biol 2010, 31:623-631.
41. Flossmann E., Rothwell P.M. British Doctors Aspirin Trial and the GBR-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369:1603-1613.
42. Liao X., Lochhead P., Nishihara R., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012, 367:1596-1606.
43. Domingo E., Church D.N., Sieber O., et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 2013, 31:4297-4305.
44. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
45. Van Cutsem E., Köhne C.H., Láng I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.
46. Sartore-Bianchi A., Martini M., Molinari F., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857.
47. Zhao L., Vogt P.K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 2008, 105:2652-2657.
48. Mao C., Yang Z.Y., Hu X.F., et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012, 23:1518-1525.
49. Perrone F., Lampis A., Orsenigo M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009, 20:84-90.
50. Engelman J.A., Chen L., Tan X., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
51. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
52. Mao M., Tian F., Mariadason J.M., et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013, 19:657-667.
53. Cully M., You H., Levine A.J., et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006, 6:184-192.
54. Yu-Fen Zhu, Bao-Hua Yu, Da-Li Li, et al. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World J Gastroenterol 2012, 18:3745-3751.
55. Smith A., Blois J., Yuan H., et al. The antiproliferative cytostatic effects of a self-activating viridin prodrug. Mol Cancer Ther 2009, 8:1666-1675.
56. Bendell J.C., Rodon J., Burris H.A., et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012, 30:282-290.
57. A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer []. ctgov:NCT01304602.
58. P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer []. ctgov:NCT01591421.
59. Hong D.S., Bowles D.W., Falchook G.S., et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012, 18(82):4173.
60. Edelman G., Bedell C., Shapiro G., et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010, 28(15s). (suppl; abstr 3004).
61. Sarker D., Ang J.E., Baird R., et al. First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2014, (Nov 4). [Epub ahead of print].
62. Juric D., Argiles G., Burris H.A., et al. Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC). Cancer Res. 2012, 72(24 (Suppl. 3)).
63. Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer []. ctgov:NCT01719380.
64. Rivero R.A., Hardwicke M.A. Identification of GSK2636771, a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinase-beta (PI3Kα) for the treatment of PTEN deficient tumors. Cancer Res 2012, 72(8 (Suppl. 1)).
65. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
66. Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients []. ctgov:NCT01337765.
67. Roper J., Richardson M.P., Wang W.V., et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS ONE 2011, 6(9):e25132.
68. Migliardi G., Sassi F., Torti D., et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012, 18:2515-2525.
69. Papadopoulos KP1, Tabernero J., Markman B., et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res 2014, 20:2445-2456.
70. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28:1075-1083.
71. Vasudevan K.M., Barbie D.A., Davies M.A., et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009, 16:21-32.
72. Yap T.A., Yan L., Patnaik A., et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011, 29:4688-4695.
73. MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma []. ctgov:NCT01333475.
74. Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Cannot Removed by Surgery []. ctgov:NCT01802320.
75. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci Signal 2009, 2(67):pe24.
76. Ng K., Tabernero J., Hwang J., et al. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin Cancer Res 2013, 19:3987-3995.
77. Wolpin B.M., Ng K., Zhu A.X., et al. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist 2013, 18:377-378.
78. Bullock K.E., Hurwitz H.I., Uronis H.E., et al. Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC). J Clin Oncol 2009, 27:4080. [abstract].
79. Altomare I., Bendell J.C., Bullock K.E., et al. Phase II trial of bevacizumab plus everolimus for refractory metastatic colorectal cancer. Oncologist 2011, 16:1131-1137.
80. Spindler K.L., Sorensen M.M., Pallisgaard N., et al. Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta Oncol 2013, 52:963-970.
81. Shahda S., Yu M., Picus J., et al. Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group. GI05-102 - final report. J Clin Oncol 2011, 29:3587. [abstract].
82. Sharma S., Reid T., Hoosen S., et al. Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC). J Clin Oncol 2009, 27:e15115. [abstract].
83. Hart L., Burris H.A., Infante J.R., et al. mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): a Sarah Cannon Research Institute phase I trial. J Clin Oncol 2011, 29:e14054. [abstract].
84. Glynn W.G., John R.W., Kimberly J., et al. Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2012, 30:600. [abstract].
85. Altomare I., Hurwitz H. Everolimus in colorectal cancer. Expert Opin Pharmacother 2013, 14:505-513.
86. Yu K., Toral-Barza L., Shi C., et al. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 2008, 7:307-315.
87. Faber A.C., Li D., Song Y., Liang M.C., et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009, 106:19503-19508.
88. Carracedo A., Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27:5527-5541.
89. Shimizu T., Tolcher A.W., Papadopoulos K.P., et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012, 18:2316-2325.
90. Rodon J., Dienstmann R., Serra V., et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013, 10:143-153.
91. Bollag G., Hirth P., Tsai J., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
92. Hanrahan A.J., Schultz N., Westfal M.L., et al. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2012, 2:56-67.
93. Kaplan R., Maughan T., Crook A., et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 2013, 31:4562-4570.
94. Coffee E.M., Faber A.C., Roper J., et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 2013, 19:2688-2698.